Table 1.
Baselines characteristics of all patients
| Characteristics | Bedaquiline group (n = 102) | Non-bedaquiline group (n = 100) | p value |
|---|---|---|---|
| Age (years, median/IQR) | 37.0 (28.0–52.0) | 43.5 (29.0–54.0) | 0.08 |
| Gender (n, %), male/female | 78 (76.5)/24 (23.5) | 71 (71.0)/29 (29.0) | 0.77 |
| Cavitary disease at baseline (n, %) | 71 (73.2) | 73 (73.0) | 0.65 |
| Concomitant extra-pulmonary TB (n, %) | 20 (19.6) | 15 (15.0) | 0.39 |
| Concomitant diabetes (n, %) | 16 (15.7) | 13 (13.0) | 0.59 |
| History of TB treatment (n, %) | 0.85 | ||
| New cases | 9 (8.8) | 8 (8.1) | |
| Previously treated cases | 93 (91.2) | 91 (91.9) | |
| Type of drug resistance (n, %) | 0.67 | ||
| RR | 3 (2.9) | 5 (5.0) | |
| MDR | 74 (72.5) | 68 (68.0) | |
| XDR | 25 (24.5) | 27 (27.0) | |
| Drug resistant rate (n, %)/n, % in XDR | |||
| Injectable agents | 83 (81.4)/25 (100.0) | 77 (77.0)/27 (100.0) | 0.44/– |
| FQs | 61 (59.8)/25 (100.0) | 55 (55.0)/27 (100.0) | 0.49/– |
| EMB | 57 (55.9)/16 (64.0) | 65 (65.0)/24 (88.9) | 0.19/0.03* |
| INH | 97 (95.1)/23 (92.0) | 98 (98.0)/26 (96.3) | 0.20/0.95 |
IQR interquartile range, M male, F female, n number, TB tuberculosis, RR rifampicin-resistant, MDR multidrug-resistant, XDR extensively drug-resistant, FQs fluoroquinolones, EMB ethambutol, INH isoniazid. Injectable agents: including Amikacin (Ak), Capremycin (Cm) and Streptomycin (Sm)
* the differences had statistical significance (p < 0.05)